BACKGROUND Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent. AIMS To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesised that 200 mg of CBD would produce a greater peak pleasant drug effect than a placebo. METHODS In a triple-blind,...
Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of...
Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system. Delta-9-tetrahydrocannabinol (THC) binds to central cannabinoid receptors, while cannabidiol (CBD) may influence endocannabinoid function without directly acting on cannabinoid receptors. We examined the effects of THC coadministered with different doses of CBD...